Trials / Completed
CompletedNCT00231426
ASSURE Study - Arrhythmia Single Shock DFT Versus ULV: Risk Reduction Evaluation With ICD Implantations
Arrhythmia Single Shock DFT Versus ULV: Risk Reduction Evaluation With ICDs Study
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- —
- Sponsor
- Boston Scientific Corporation · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- —
Summary
The ASSURE Study will evaluate shock conversion performance when programming the first shock of an implantable cardioverter-defibrillation (ICD) is based on an implant test consisting of either 1) a single induction of ventricular fibrillation (VF) and subsequent demonstration conversion success at 14 J or 2) an upper limit of vulnerability (ULV) test at 14 J.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DEVICE | ICD |
Timeline
- Start date
- 2003-06-01
- Completion
- 2005-11-01
- First posted
- 2005-10-04
- Last updated
- 2006-11-22
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT00231426. Inclusion in this directory is not an endorsement.